Clinical Data ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma Pharmaceutical TechnologyEarly data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca's ESOT-01.HematologyRead full story pharminent June 2, 2026 (Last updated: June 3, 2026) Pharmaceutical Technology Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ESOT-01. Hematology Read full story Post navigation Previous: ASCO26: In vivo oncology approaches continue to show promiseNext: Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
